With December ticking toward its end, 2024 is just about ready to fall off the calendar. It's been an absolutely wonderful performance stretch for the broader market, and hot tech companies including Nvidia , Palantir , and Apple have rocketed to new valuation highs. But there are also some great technology stocks out there that are trading well below previous pricing heights, and investors could be doing themselves a disservice by overlooking these great companies. If you're on the hunt for investments that can deliver big wins in 2025 and beyond, read on to see why two Fool.com contributors think these beaten-down stocks are great buys right now. AMD is an undervalued AI stock play Keith Noonan : Advanced Micro Devices ( AMD 0.10% ) is a designer of central processing units (CPUs) and GPUs for personal computers and data centers. The company's stock is up roughly 182% over the last five years thanks to some solid business execution and excitement that the company could be poised to see some of the same explosive, AI-driven growth that has propelled Nvidia to stellar returns. On the other hand, AMD has seen a slower ramping for AI-related processors than some investors expected -- and the disconnect in the timeline has caused some significant valuation pullback for the stock. The chip specialist's share price is now down roughly 40% from the lifetime high that it hit earlier this year. Despite a strong rally for the broader market, AMD stock has tumbled over the last few months -- and the company's share price has yet to recover from sell-offs triggered by its third-quarter earnings release at the end of October. AMD's revenue grew roughly 18% year over year to reach $6.8 billion in the period. Meanwhile, non-GAAP (adjusted) earnings per share rose 31% compared to the prior-year period. While AMD will continue to have a strong market presence in processors for gaming and personal computers, it's the data center segment that has really become central to the stock's performance. Last quarter saw sales for the AI-related segment increase to $3.5 billion -- up 122% year over year and 25% on a sequential quarterly basis. The performance actually topped Wall Street's expectations and pushed the business to overall sales and earnings beats in the quarter, but some investors and analysts didn't think the company's guidance was bullish enough. AMD has tended to err on the conservative side lately when it comes to issuing guidance, and it wouldn't be surprising to see significant near-term gains kicked off by Q4 numbers that come in better than broadly expected. But more importantly for long-term investors, the business remains poised to benefit from the unfolding AI revolution. The company's competitive positioning in the highly lucrative GPU category isn't as as strong as Nvidia's, but AMD's lagging stock performance opens the door for investors who buy shares at today's prices to see big gains. Aehr Test Systems is a buy for enterprising investors Lee Samaha : It's fair to say it hasn't been a vintage year for the provider of burn-in testing equipment to the chip industry. Aehr Test Systems ( AEHR 1.35% ) makes silicon carbide chip testing equipment, and its primary growth market comes from its use in electric vehicles ( EVs ). Silicon carbide chips have qualities that make them more efficient than silicon in power electronics, making them ideal for EVs. There's little doubt that the adoption of silicon carbide chips will grow, fueling demand for Aehr's solutions. However, growth expectations for both the chips and Aehr's sales have been pared back this year due to the slowing growth of EV sales, which has caused automakers to defer investment in production lines. As a result, the company's share price is down roughly 72% from its lifetime high as of this writing. Still, the slowdown -- primarily related to relatively high interest rates -- is unlikely to last forever, and no one disputes that EVs are the transportation industry's future. In addition, Aehr recently inked a deal to sell an initial $10 million worth of equipment to an artificial intelligence customer. The agreement helps diversify Aehr's end markets and customer base and de-risks the stock. With the company successfully opening new end markets and a likely recovery in its EV end markets, Aehr Test Systems has plenty of potential to grow. Now could be an opportune time to buy the stock.Protecting freedom is how we keep our children safeNone
Shares of Mineralys Therapeutics, Inc. ( NASDAQ:MLYS – Get Free Report ) traded down 4.1% during mid-day trading on Thursday . The company traded as low as $12.11 and last traded at $12.28. 6,387 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 179,628 shares. The stock had previously closed at $12.80. Wall Street Analysts Forecast Growth Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a report on Tuesday, November 12th. View Our Latest Analysis on Mineralys Therapeutics Mineralys Therapeutics Stock Performance Mineralys Therapeutics ( NASDAQ:MLYS – Get Free Report ) last announced its earnings results on Monday, November 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same quarter in the prior year, the business posted ($0.57) earnings per share. Sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current year. Insiders Place Their Bets In other Mineralys Therapeutics news, insider David Malcom Rodman sold 25,482 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the transaction, the insider now directly owns 135,974 shares of the company’s stock, valued at $2,043,689.22. This trade represents a 15.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . Also, CEO Jon Congleton sold 15,271 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.52, for a total transaction of $206,463.92. Following the completion of the sale, the chief executive officer now owns 895,941 shares in the company, valued at approximately $12,113,122.32. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold 51,510 shares of company stock worth $735,431 in the last three months. 33.24% of the stock is owned by insiders. Institutional Inflows and Outflows A number of large investors have recently bought and sold shares of the company. Franklin Resources Inc. raised its position in shares of Mineralys Therapeutics by 17.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,745,513 shares of the company’s stock valued at $21,138,000 after acquiring an additional 262,922 shares in the last quarter. Caligan Partners LP increased its stake in Mineralys Therapeutics by 31.6% during the third quarter. Caligan Partners LP now owns 981,155 shares of the company’s stock valued at $11,882,000 after purchasing an additional 235,397 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Mineralys Therapeutics by 60.1% during the second quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company’s stock worth $6,230,000 after purchasing an additional 200,000 shares during the period. Ikarian Capital LLC acquired a new stake in shares of Mineralys Therapeutics during the third quarter worth $2,180,000. Finally, Driehaus Capital Management LLC lifted its position in shares of Mineralys Therapeutics by 40.4% in the 2nd quarter. Driehaus Capital Management LLC now owns 257,371 shares of the company’s stock worth $3,011,000 after buying an additional 74,074 shares during the last quarter. Institutional investors own 84.46% of the company’s stock. Mineralys Therapeutics Company Profile ( Get Free Report ) Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. Featured Stories Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
UConn head coach Dan Hurley insists he's not overvaluing Wednesday night's game between his 25th-ranked Huskies and No. 15 Baylor in Storrs, Conn. Sure, it comes on the heels of the two-time reigning national champion Huskies (5-3) responding to losing all three games during the Maui Invitational with a blowout victory over Maryland Eastern Shore on Saturday.